CompaniesInvestorsPeople
Home
Loading

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

aVenture is in Beta: research coverage is expanding as we build, so please independently verify key details before making investment decisions.

Get in Touch

  • Contact

  • Request a Demo

  • Request Data Updates

  • Add a Company

Research

  • Companies

  • Investors

  • People

aVenture

  • Download App

  • Pricing

Download the aVenture Research beta for iOS and iPadOSDownload aVenture Research on the Mac App Store

Resources

  • Documentation

  • Use Cases

  • CLI

  • MCP

  • Feature Requests

  • Sitemap

Member

Backed by

Ask AI about aVenture

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy · Terms of Service

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading
Home›
Companies›
Hologic›
Library
Hologic

Hologic

Hologic develops diagnostics, imaging, and surgical technologies for detecting and treating women's health conditions.

Operating headquarters
Marlborough, MA, US🇺🇸
Founded
1985
Loading
Overview
M & A
Compare
Employees
News
Library

Hologic - Library

hologic.com·Crawled Oct 9, 2026·

Topics

Publication type

Content origin
Row density

Product

6 pages
  1. FaxitronPath® Digital Pathology System/FaxitronPath

    FaxitronPath® is designed for digital pathology imaging and specimen analysis in surgical pathology settings. Explore system features, workflow integration, and ordering resources.

  2. Horizon® DXA System | Bone Density & Body Composition/horizondxa

    The Horizon® DXA System is designed for bone density measurement and body composition analysis. Explore system capabilities, clinical applications, and technical specifications.

  3. Product Ideas/product-ideas

    Thank you for interest in Hologic and in our products. While we appreciate your interest in improving our products, we also want to make sure that both your and Hologic's confidential information and/or intellectual property interests are properly protected

  4. ReadyandResilient/readyandresilient

Blog

6 pages
  1. Deborah Koyle: Rising Above Cancer, Anchored by Family/deborah-koyle-rising-above-cancer-anchored-family
  2. Diagnostics Decoded/diagnosticsdecoded
  3. Scientific Publications - Breast Health/medical-education/scientific-publications-breast

    Breast Tomosynthesis (3D Mammography™) Smith_WhitePaper_2017_Improving Patient Comfort in Mammography

  4. Scientific Publications - Skeletal Health/medical-education/scientific-publications-skeletal

    Body Composition Mountjoy_British Journal of Sports Medicine_2014_The IOC consensus statement: beyond the Female Athlete Triad_Relative Energy Deficiency in Sport (RED-S) Trexler_Journal of Strenght and Conditioning Research_2017_Fat-Free Mass Index in NCAA Division I and II Collegiate American Football Players

Press

6 pages
  1. AACC 2023/aacc-2023
  2. Antimicrobial Resistance 2022/antimicrobialresistance2022
  3. CVS 2023/cvs-2023
  4. IAS 2023/ias-2023

Team

1 page
  1. Leadership/leadership

About

6 pages
  1. Acquisition Information/acquisition

    Hologic to be Acquired by Blackstone and TPG

  2. Global Access Initiative/global-access-initiative

    Hologic's Global Access Initiative expands access to molecular diagnostics across low- and middle-income countries through all-inclusive pricing and partnerships.

  3. Global Access Initiative/globalaccessinitiative
  4. Governance Documents/governance

    Governance documents available after Hologic was acquired by Blackstone and TPG.

Contact

5 pages
  1. A Message From Our Chairman, President and CEO/message-our-chairman-president-and-ceo
  2. Customer Service & Product Support/contact-us

    Contact Hologic for customer service, product support, clinical applications assistance, and general inquiries. Find the right contact for your region and request type.

  3. Other Contact Us/other-contact-us
  4. SureCare® - Contact Us/surecare-contact-us

Homepage

1 page
  1. Homepage/

    Hologic develops diagnostics, surgical, and medical imaging technologies designed to advance women's health. Explore products and clinical resources.

Privacy

4 pages
  1. Additional Disclosures for the EEA/additional-disclosures-eea

    .anchor{ display: block; height: 110px; /*same height as header*/ margin-top: -110px; /*same height as header*/ visibility: hidden; } Last Revised: July, 2022

  2. Additional-disclosures-for the-EEA-and-UK/additional-disclosures-eea-and-uk

    ADDITIONAL DISCLOSURES FOR THE EEA AND UK

  3. Privacy Policy/privacy-policy
  4. Subprocessors/subprocessors

Terms & Conditions

4 pages
  1. AdvaMed Code of Ethics/advamed-code-ethics
  2. Hologic Sales Terms & Conditions/hologic-sales-terms-conditions
  3. Terms & Conditions/terms-conditions
  4. Terms of Use Agreement/self-service-terms

    Please read this Terms of Use Agreement (hereinafter the “Agreement”) carefully before clicking the “I Agree” button, accessing or using the Hologic Support Portal self-service customer support website and its Services (hereinafter the “Support Portal”).

Coverage

6 items
  1. 1 in 3 U.S. Women Skipped or Delayed a Recommended Mammogramhologic.com/about/press-release/more-one-three-us-women-have-skipped-or-delayed-recommended-mammogram

    Hologic reports that a survey of more than 1,000 U.S. women found one in three had skipped or delayed a recommended mammogram. The survey points to access barriers and confusion about costs as factors that can keep women from screening.

    Oct 2026 · HologicNews article

  2. Breast Cancer Index Registry Study in JAMA Network Openhologic.com/about/press-release/new-data-shows-physicians-changed-extended-endocrine-therapy-recommendations

    Breast Cancer Index test results led physicians to change extended endocrine therapy recommendations for 42% of patients. The finding comes from a registry study published in JAMA Network Open.

    Sep 2026 · HologicNews article

  3. Fluent Pro Fluid Management System Wins IDEA Design Award | Hologichologic.com/about/press-release/hologics-fluent-pro-system-wins-international-design-excellence-award-user

    Hologic's Fluent Pro fluid management system wins an International Design Excellence Award (IDEA) for its user-centric design in hysteroscopy.

    Sep 2026 · hologic.comNews article

  4. Aptima HPV Assay CE-IVDR Mark Expanded, EU and UKhologic.com/about/press-release/ce-ivdr-mark-hologics-aptima-hpv-test-expanded-include-self-collected-sample

    Hologic’s Aptima HPV Assay receives an expanded CE-IVDR mark in the European Union and the UK, extending its use to self-collected vaginal samples taken in a healthcare setting. The announcement specifies this sample type and setting but provides no further details about the expansion.

    Jul 2026 · HologicNews article